Arch Pharmalabs Ltd. and Orochem Technologies Inc. are joining forces to enhance pharmaceutical purification processes. The exclusive agreement leverages Orochem's innovative Simulated Moving Bed (SMB) technology, promising higher purities and cost-effective API production.
In a move poised to revolutionize pharmaceutical manufacturing, Arch Pharmalabs Ltd., India, has announced an exclusive Technology Access & Services Agreement with Orochem Technologies Inc., USA. This partnership centers around utilizing Orochem's proprietary Simulated Moving Bed (SMB) platform for pharmaceutical and other critical applications, setting the stage for significant advancements in purification technology.
The core of this collaboration lies in the SMB technology, a highly sophisticated chromatographic separation process. This technology allows for the efficient separation of chemical compounds, yielding substantial quantities of purified or enriched materials at a lower cost than traditional batch chromatography methods. The implications are vast, particularly for producing Active Pharmaceutical Ingredients (APIs), nutritional supplements, fatty acids, and specialty sugars with unparalleled purity at industrial scales.
Ajit Kamath, Chairman & Managing Director of Arch Pharmalabs Ltd., expressed enthusiasm about the collaboration, stating, "We are extremely excited with the technology collaboration we have signed with Orochem Technologies Inc. for use of their proprietary SMB process, under license to us for various applications." He further highlighted the potential for Arch Pharmalabs to offer unique solutions to the pharma industry worldwide, leveraging its USFDA-approved facilities in India and the Vitalife facility in Gurgaon for contract manufacturing of APIs.
Dr. Asha Oroskar, CEO of Orochem Technologies Inc., echoed this sentiment, noting, "We are very pleased with this new partnership with Arch Pharmalabs… The commercialization of the SMB Technology allows Worldwide Pharma and Nutraceutical Industry an avenue to shorten product development cycle time for new and generic active ingredients.” With 25 years of experience in commercializing SMB Chromatography Technology globally, Orochem's expertise combined with Arch Pharmalabs' manufacturing capabilities promises to be a game-changer.
This strategic alliance is expected to unlock vast opportunities for Arch Pharmalabs in the separation and purification of small molecule APIs, enhancing its competitive edge and contributing to the advancement of pharmaceutical production on a global scale. The partnership signals a positive trajectory for both companies and the broader pharmaceutical industry.
